Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response - Fleischmann, RM; Genovese, MC; Enejosa, JV (Ann Rheum Dis, 2019)